We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.22 | 1.71% | 13.12 | 13.12 | 13.13 | 13.44 | 12.03 | 12.31 | 9,345,569 | 17:31:32 |
From May 2022 to May 2024
By Kathryn Hardison
Novavax Inc. has received emergency use authorization from the U.S. Food and Drug Administration for its protein-based Covid-19 booster for adults.
The vaccine has been approved as a first booster dose for people of at least 18 years of age who received a primary Covid-19 vaccination at least six months prior, the biotechnology company said Wednesday.
The booster is authorized for adults without access to an FDA-authorized mRNA bivalent booster vaccine and for adults who would otherwise not receive a booster, the company said.
The next step is a policy recommendation for use as a first booster from the Centers for Disease Control and Prevention, Novavax said.
The vaccine also is available for use as a booster in adults aged 18 and older in the European Union, Japan, Australia, New Zealand, Switzerland and Israel.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
October 19, 2022 11:40 ET (15:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
